Table 1.

Healthy volunteers (HV) and systemic sclerosis (SSc) patients characteristics

			HV	SSc
Demography
Age		n	365	249
		Median (Q1;Q3)	53 (47;59)	60 (50;68)
Sex		n	365	249
	Female	n (%)	307 (84)	212 (85)
Race		n	365	249
	Asian	n (%)	3 (0.8)	2 (0.8)
	Black/African American	n (%)	0 (0)	0 (0)
	Caucasian/White	n (%)	360 (98.6)	245 (98.4)
	Native Hawaiian/Pac. Isl.	n (%)	0 (0)	1 (0.4)
	Other	n (%)	2 (0.5)	1 (0.4)
Autoantibodies
Cent B		n	237	211
	Positive	n (%)	0 (0)	105 (49.8)
SCL70		n	238	208
	Positive	n (%)	1 (0.4)	79 (38.0)
SSA		n	238	207
	Positive	n (%)	6 (2.5)	36 (17.4)
SSB		n	238	211
	Positive	n (%)	1 (0.4)	4 (1.9)
U1 RNP		n	238	208
	Positive	n (%)	12 (5)	17 (8.2)
Clinical features
Pericarditis		n	-	232
	No	n (%)	-	225 (97.0)
	Past	n (%)	-	5 (2.2)
	Present	n (%)	-	2 (0.9)
Systemic hypertension		n	-	249
	Yes	n (%)	-	80 (32.1)
Pulmonary fibrosis		n		231
	Yes	n (%)	-	86 (37.2)
Skin fibrosis		n	-	248
	No	n (%)	-	74 (29.8)
	Past	n (%)	-	5 (2.0)
	Present	n (%)	-	169 (68.1)
DLCO		n	-	126
	% predicted value	Median (Q1;Q3)	-	64 (49 ;75)
Forced vital capacity		n	-	131
	% predicted value	Median (Q1;Q3)	-	94 (79;109)
SSc classificationa		n	-	141
	dcSSc	n (%)	-	49 (34.8)
	lcSSc	n (%)	-	64 (45.4)
	ssSSc	n (%)	-	28 (19.8)
Treatment		n	-	249
Hydroxychloroquine	Yes	n (%)	-	21 (8.4)
Immunosuppressants	Yes	n (%)	-	65 (26.1)
Biologicals	Yes	n (%)	-	7 (2.8)
Steroids	Yes	n (%)	-	59 (23.7)
Systemic antibiotics	Yes	n (%)	-	5 (2.0)

DLCO diffusing capacity of the lungs for carbon monoxide, HV healthy volunteers, Pac. Isl. Pacific islanders, dcSSc diffuse cutaneous SSc, lcSSc limited cutaneous SSc, ssSSc sine scleroderma SSc.

^aSSc classification was performed on 141 out of 249 patients. n, number of patients with available information.